Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of M/I Homes (NYSE: MHO ) fell as much as 10% today after the company released earnings.
So what: Revenue jumped 37%, to $234.6 million, in the second quarter, and net income nearly doubled, to $6.05 million, or $0.25 per share. But analysts were expecting $258 million in revenue, and earnings of $0.36 per share, so results were still behind estimates.�
Now what: Disappointing results were a theme for homebuilders today, and investors and analysts may have gotten ahead of themselves in expectations for the housing recovery. To make matters worse, interest rates are up, and buyers will be pressured by higher mortgage costs, which could suppress sales going forward. M/I Homes still trades at just nine times forward estimates and is seeing strong growth, so I don't think this report is reason to panic. It may, however, be time to lower expectations a bit for the industry.
Interested in more info on M/I Homes? Add it to your watchlist by clicking here.
Best Gas Utility Stocks For 2015: Cliffs Natural Resources Inc (CLV)
Cliffs Natural Resources Inc. is an international mining and natural resources company. The Company is an iron ore producer and a producer of metallurgical coal. The Company�� operations are organized according to product category and geographic location: U.S. Iron Ore, Eastern Canadian Iron Ore, North American Coal, Asia Pacific Iron Ore, Asia Pacific Coal, Latin American Iron Ore, Ferroalloys, and its Global Exploration Group. The Company operates in four segments: U.S. Iron Ore, Eastern Canadian Iron Ore, North American Coal and Asia Pacific Iron Ore. In the United States, it operates five iron ore mines in Michigan and Minnesota, five metallurgical coal mines located in West Virginia and Alabama and one thermal coal mine located in West Virginia. It also operates two iron ore mines in Eastern Canada that primarily provide iron ore to the seaborne market for Asian steel producers. Its Asia Pacific operations include two iron ore mining complexes in Western Australia, serving the Asian iron ore markets with direct-shipping fines and lump ore, and a 45% interest in a coking and thermal coal mine located in Queensland, Australia. In Latin America, it has a 30% interest in Amapa, a Brazilian iron ore project, and in Ontario, Canada, it has a chromite project in the pre-feasibility stage of exploration. On May 12, 2011, the Company completed the acquisition of Consolidated Thompson Iron Mining Limited.
U.S. Iron Ore and Eastern Canadian Iron Ore
The Company is a global iron ore producer, primarily selling production from U.S. Iron Ore to integrated steel companies in the United States and Canada, and production from Eastern Canadian Iron Ore to the seaborne market for Asian steel producers. The Company manages and operates five iron ore mines located in Michigan and Minnesota and two iron ore mines in Eastern Canada. As of December 31, 2011, the United States-based mines and one of the mines in Eastern Canada had an annual rated capacity of 38.5 million gross tons of iron or! e pellet production. The second iron ore mine that the Company manages and operates in Eastern Canada had an annual rated capacity of 8.0 million gross tons of iron ore concentrate as of December 31, 2011. During the year ended December 31, 2011, the Company produced a total of 31.0 million tons of iron ore pellets at U.S. Iron Ore, including 23.7 million tons for its account and 7.3 million tons on behalf of steel company partners of the mines.
At Eastern Canadian Iron Ore, it produced a total of 6.9 million metric tons of iron ore pellets and concentrate during 2011, with concentrate production measured from the date of its acquisition of Consolidated Thompson in 2011. The Company produces various grades of iron ore pellets, including standard, fluxed and high manganese, for use in its customers��blast furnaces as part of the steelmaking process. As of December 31, 2011, it had approximately 1.2 million tons of pellets, respectively, in inventory at lower lakes or customers��facilities. During 2011, the Company sold 24.2 million tons of iron ore pellets, respectively, from its share of the production from the Company�� U.S. Iron Ore mines. Its Eastern Canadian Iron Ore revenues are derived from sales of iron ore pellets and concentrate to the seaborne market for Asian steel producers. The iron ore pellets produced by Eastern Canadian Iron Ore are sold to various customers. During 2011, the Company sold 7.4 million metric tons of iron ore pellets and concentrate, respectively, from its Eastern Canadian Iron Ore mines.
North American Coal
The Company owns and operates five metallurgical coal mines located in West Virginia and Alabama and one thermal coal mine located in West Virginia that had a rated capacity of 9.4 million tons of production annually in 2011. In 2011, the Company sold a total of 4.2 million tons. North American Coal�� metallurgical coal production is sold to global integrated steel and coke producers in Europe, Latin America and North Am! erica, an! d its thermal coal production is sold to energy companies and distributors in North America and Europe.
Asia Pacific Iron Ore
The Company�� Asia Pacific Iron Ore operations are located in Western Australia and include its wholly owned Koolyanobbing complex and its 50% interest in Cockatoo Island. Production in 2011, was 8.9 million metric tons. These two operations supply a total of three direct-shipping export products to Asia via the global seaborne trade market. Koolyanobbing produces a standard lump and fines product. Cockatoo Island produces a single premium fines product. The lump products are directly fed to blast furnaces, while the fines products are used as sinter feed. Koolyanobbing is a collective term for the operating deposits at Koolyanobbing, Mount Jackson and Windarling. There are approximately 60 miles separating the three mining areas. Cockatoo Island is located off the Kimberley coast of Western Australia, approximately 1,200 miles north of Perth Cockatoo Island produces a single high-grade iron ore product known as Cockatoo Island Premium Fines. During 2011, it sold 8.6 million metric tons of iron ore from its Western Australia mines.
The Company competes with ArcelorMittal Mines Canada, U.S. Steel Canada Inc., Alpha Natural Resources, Inc., Patriot Coal Corporation, CONSOL Energy Inc., Arch Coal, Inc., Walter Energy, Inc., Peabody Energy Corp. Anglo, BHP and Fortescue Metals Group Ltd., Rio Tinto plc, Vale, BHP, Teck Resources Limited and Xstrata plc.
Advisors' Opinion:- [By Henry Nyce]
Cliffs Natural Resources (CLV) closed at $18.55 yesterday. At that price CLV offers 10.5% per share. Originally offered at $25.00 per share, CLV can now be purchased well below the offering price. It is designed to pay distributions of 7.00% per annum ($1.75 per annum or $0.4375 per quarter) to be paid quarterly on 2/1, 5/1, 8/1 & 11/1 to holders of record on the immediately preceding 1/15, 4/15, 7/15 & 10/15 respectively.
Top 5 Diversified Bank Companies To Buy Right Now: CNH Industrial NV (CNHI)
CNH Industrial NV is a Netherlands-based company primarily engaged in the manufacture of heavy machinery and vehicles equipment. It divides its activities into four main businesses. The Agricultural Equipment offers agricultural equipment under the New Holland Agriculture, Case IH brands and the Steyr brand. The Construction Equipment produces excavators, bulldozers, backhoes, compactors and other construction equipment under the New Holland Construction and Case Construction Equipment brands. The Trucks & Commercial Vehicles manufactures trucks and a commercial vehicles, including buses, coaches and special vehicles under Iveco, Iveco Bus and Heuliez Bus brands, as well as it produces quarry and mining equipment through Iveco Astra, and fire fighting vehicles through the Iveco Magirus brand. The Powertrain offers transmission systems, engines for marine application and power generation through FPT Industrial brand. Advisors' Opinion:- [By Lisa Levin]
CNH Industrial NV (NYSE: CNHI) shares tumbled 2.47% to reach a new 52-week low of $11.44. CNH Industrial reported an 11% drop in its third-quarter profit.
Top 5 Diversified Bank Companies To Buy Right Now: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By David Williamson]
It looks like the CHMP, Europe's version of the FDA advisory committee, didn't want the month to end without two big positive opinions, giving investors a nice little present heading into the weekend.�Celgene's (NASDAQ: CELG ) relapsed and refractory multiple myeloma drug pomalidomide, and Aegerion's (NASDAQ: AEGR ) HoFH drug Juxtapid, are now likely to be approved in the EU.
- [By Ben Levisohn]
Remember when biotech stocks like Gilead Sciences (GILD) and Celgene (CELG) were getting creamed and everyone was wondering if the biotech boom was finished? Yeah, neither do I.
Top 5 Diversified Bank Companies To Buy Right Now: SemiLEDS Corporation(LEDS)
SemiLEDs Corporation engages in the development, manufacture, and sale of light emitting diode (LED) chips and LED components. Its products are used primarily for general lighting applications, including street lights and commercial, industrial, and residential lighting, as well as in backlighting, medical, automotive, and ultra violet (UV) applications. The company markets blue, green, and UV LED chips under the MvpLED brand name primarily to customers in China and Taiwan, as well as in Russia and North America. It sells LED chips to packagers and distributors, who in turn sell to packaging customers. SemiLEDs Corporation was founded in 2005 and is based in Miao-Li County, Taiwan.
Advisors' Opinion:- [By Victor Selva]
On Nov. 21, Robert Karr bought Veeco Instruments Inc. (VECO), a company that designs, manufactures and markets equipment to make light emitting diodes (LEDs), solar panels, hard-disk drives and other devices.
- [By Stock Investor]
Next up I will look at SemiLEDs Corporation (LEDS). This company is based in China, typically a red flag from the start. In the last year LEDS posted almost $26m in revenue with a net cash balance of approximately $36m. The market cap here is a small $42m, much cheaper than RVLT. LEDS has an average quarterly cash burn of about $5m, leaving them ample funding for the next two years at current spend rates. So far the financials here suggest that LEDS is undervalued, especially when compared to RVLT. Usually, however where there is smoke there is fire. In 2012 LEDS lost a patent infringement suit against CREE Inc (CREE). The settlement prevents LEDS from selling it product in the US, a major red flag. This is also the likely reason for such a large drop in sales over the last year of almost 40%. Revenue for the second quarter of fiscal 2013 was $4.8 million, a 39% decrease compared to $7.9 million in the second quarter of fiscal 2012. It is disconcerting that a company in a sector that is supposedly experiencing record growth, is seeing its sales drop this much. A major red flag for investors. While the cash position is a positive, investors should note that this is a China based company. Accurate financials are not something Chinese companies are know for.
- [By Paul Ausick]
Just a week earlier SemiLEDS Corp. (NASDAQ: LEDS) said that it had received a delisting notice from Nasdaq for failing to maintain a share price of at least $1 a share. The company also faced several class action lawsuits as earnings tanked after a dramatic run-up in April. Shares rose nearly 15% after Revolution�� October announcement.
No comments:
Post a Comment